Disclaimer:
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi suscipit at nunc id suscipit. Phasellus tincidunt dui at eros tempor suscipit. Etiam ultrices massa quis luctus dictum. Quisque eget elit urna. Praesent quis suscipit eros, vel molestie massa. Morbi semper justo sodales suscipit accumsan. Praesent porta aliquet magna nec malesuada. Phasellus ut hendrerit nisi, non sagittis turpis.
- Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics
- Therapeutics for Eliminating Hepatitis B Virus cccDNA (R21/R33 Clinical Trial Not Allowed)
- Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Not Allowed
- Cooperative Centers on Human Immunology (U19 Clinical Trial Optional)
- Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
- HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)
- Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
- Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)
- Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
- Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed)
- Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)
- Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 - Clinical Trial Not Allowed)